The startup’s first disease target is chronic inflammatory demyelinating polyneuropathy (CIDP), which can be treated with a blockbuster Argenx drug. Nuvig aims to show its drug can offer a better way to treat this disease and other autoimmune conditions. The post Nuvig Therapeutics Nabs $161M to Build Case for a Better Approach to Autoimmune Disease…
[Sponsored] Mayo Clinic has developed a new tool that could speed up the time it takes for digital health companies to validate their tech to hospitals. The post Mayo Clinic Platform Program to Help Clinical Digital Health Startups Succeed appeared first on MedCity News.
President Donald Trump’s latest executive order aims to strengthen enforcement for CMS’ price transparency requirements. Some experts think greater price transparency could reduce healthcare costs by fostering more competition, while others are concerned about the potential effects on hospital-payer negotiations, as well as the practicality of enforcing these requirements. The post The Promise and Peril…
Value-based care contracting is especially difficult for behavioral health providers, Taft Parsons III, chief psychiatric officer at CVS Health/Aetna, pointed out during a conference this week. The post Aetna Exec: Payers Need to Stop Making Behavioral Health Providers Jump Through Hoops In Order to Participate in Value-Based Care appeared first on MedCity News.
A strong public health system can make a big difference for those who face stark health disparities. But epidemiologists serving Native American communities, which have some of the nation’s most profound health inequities, say they’re hobbled by state and federal agencies restricting their access to important data. American Indians and Alaska Natives face life expectancy…
Regulus Therapeutics drug farabursen is a potential first-in-class treatment for a rare kidney disease whose only FDA-approved therapy introduces severe toxicity risks. Farabursen is joining a Novartis drug lineup spanning several therapies for rare renal disorders. The post Novartis Gets Phase 3-Ready Rare Kidney Disease Drug via $800M Regulus Acquisition appeared first on MedCity News.
In Medicare Physician Fee Schedule Final Rules from recent years, the administration made changes to Medicare payment policies for certain dental services, in addition to other payment and policy changes. The 2023 rule clarified CMS’s interpretation of when medically necessary dental services can be covered and codified certain payment policies, and the 2023, 2024, and…